文献速递慢性肾脏病遗传性与小管间质肾病

托伐普坦治疗常染色体显性多囊肾病长期效果的汇总数据分析

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD.
PubMed 文献 · Kidney Int Rep · 2022-02-19

本研究汇总8项托伐普坦临床试验与5项未使用托伐普坦的常染色体显性多囊肾病研究数据,比较5.5年内估算肾小球滤过率与总肾脏体积的变化率。匹配分析显示托伐普坦使年化估算肾小球滤过率下降减缓1.01 ml/min per 1.73 m2(P < 0.001),总肾脏体积在第1、3、5年显著降低。

要点

  • 匹配分析每组1186例,托伐普坦使5.5年内年化eGFR下降减缓1.01 ml/min per 1.73 m2(P < 0.001)。
  • 全数据集分析(托伐普坦2928例,标准治疗4189例)确认年化eGFR下降显著减少。
  • 有总肾脏体积数据的受试者中,托伐普坦组第1、3、5年总肾脏体积较标准治疗组显著降低。

核心结论

  • 汇总的托伐普坦队列与常染色体显性多囊肾病对照队列比较,支持托伐普坦的长期治疗效应。

研究设计与样本

  • 汇总的纵向分析,纳入8项托伐普坦临床试验和5项未使用托伐普坦的研究(自然病史或标准治疗)的常染色体显性多囊肾病患者数据。
  • 对参与多项研究的受试者数据进行链接以延长随访,评估5.5年内估算肾小球滤过率和总肾脏体积的变化率。
  • 为控制托伐普坦组与标准治疗组间疾病特征的异质性,构建了基线人口学和疾病特征匹配的分析人群。

主要发现

  • 匹配分析每组1186例,托伐普坦较标准治疗在5.5年内使年化估算肾小球滤过率下降减缓1.01 ml/min per 1.73 m2(P < 0.001)。
  • 全数据集分析(托伐普坦2928例,标准治疗4189例)确认年化估算肾小球滤过率下降显著减少。
  • 在有总肾脏体积数据的受试者中,匹配和全数据集分析均显示托伐普坦组第1、3、5年总肾脏体积较标准治疗组显著降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 1- and 3-year randomized trials, tolvaptan slowed kidney function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. The 3-year trial also evaluated effects on total kidney volume (TKV); slowing of TKV growth was demonstrated. Subjects were followed in open-label extension trials. To characterize longer-term effects of treatment, an analysis was conducted comparing tolvaptan-treated subjects with subjects from standard of care (SOC) ADPKD studies without tolvaptan. METHODS: This was a pooled, longitudinal analysis of data from 8 tolvaptan clinical trials and 5 studies without tolvaptan (natural history or SOC) in ADPKD. Data from subjects who participated in multiple studies were linked for longer follow-up. Outcomes were rates of change in estimated glomerular filtration rate (eGFR) and TKV over 5.5 years. To control for heterogeneity in disease characteristics between tolvaptan and SOC treatment groups, analysis populations matched for baseline demographic and disease characteristics were constructed. RESULTS: Matched analysis (n = 1186 in each treatment group) indicated that tolvaptan slowed annualized eGFR decline by 1.01 ml/min per 1.73 m2 (P < 0.001) versus SOC over 5.5 years. An analysis conducted on the full, unmatched data set (tolvaptan: n = 2928; SOC: n = 4189) confirmed significant reduction in annual eGFR decline. Among subjects with TKV data, TKV was significantly reduced at years 1, 3, and 5 for tolvaptan versus SOC in both matched and full data sets. CONCLUSION: Comparison of a pooled tolvaptan cohort to a pooled control cohort with ADPKD supports longer-term treatment effects of tolvaptan.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Zhou X, Davenport E, Ouyang J, et al. Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD. Kidney Int Rep. 2022. PMID: 35570988. doi:10.1016/j.ekir.2022.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。